In February 2015, a license agreement was signed with Serum Institute of India Ltd. (Serum Institute) for GTL003, a Vaxiclase technology for use as an antigen in the development of acellular multivalent combination vaccines containing pertussis antigens.

Serum Institute ( is the world's largest producer of the measles and DTP group of vaccines. Two of every three children immunized globally are vaccinated with a product manufactured by Serum Institute.

Since the beginning of the agreement, Genkyotex has received a total of $1.3 million in an upfront payment and from the achievement of a pre-specified development milestone in November 2016. According to the terms of the initial agreement, Genkyotex is eligible to receive $57 million. Following the expansion of the agreement to the developed world territories in June 2018, Genkyotex is now eligible to receive an additional €100 million, bringing the overall agreement to approximately €150 million*.Genkyotex is also eligible to receive single digit royalties on sales.